Wednesday, February 08, 2017 1:27:18 PM
http://cardiobrief.org/2017/02/08/enormous-rivaroxaban-study-stopped-early-for-overwhelming-efficacy/
http://www.news.bayer.com/baynews/baynews.nsf/id/BAF21410A6C41901C12580C10052A834/$File/2017-0041E.pdf?open&mod=08.02.2017_16:43:04
"Oral anticoagulant reduced CV events in patients with coronary and peripheral disease.
The very large COMPASS study has been stopped early for “overwhelming efficacy,” according to a press release issued by Bayer AG and Janssen, manufacturers of rivaroxaban (Xarelto).
The phase 3 trial randomized 27,402 patients with coronary artery disease (CAD) and peripheral artery disease (PAD) to receive either rivaroxaban 2.5 mg twice daily in addition to aspirin 100 mg once daily, rivaroxaban 5 mg twice daily alone, or aspirin 100 mg once daily alone. The trial was stopped a year ahead of its scheduled completion date following a recommendation by the Data Monitoring Committee. The primary endpoint of the study was the first occurrence of either MI, stroke, or CV death. The DMC said the trial had reached its prespecified criteria for superiority.
In an open-label extension trial patients enrolled in the study will be offered rivaroxaban “owing to the magnitude of effect and the confirmation of the existing safety profile of rivaroxaban,” the companies announced.
COMPASS is the first new oral anticoagulant to be studied in this patient population, the announcement said. Full results of the study will be presented later this year at a major medical meeting.
“Although there are therapies that offer significant protection for patients with coronary or peripheral artery disease, a significant risk of heart attacks, stroke or even death remains in these high-risk patients,” said Salim Yusuf (McMaster University), Principal Investigator of the COMPASS study, in a press release issued when the trial was initiated. “This is therefore an important study, designed to investigate additional, potentially complementary, cardioprotective benefits for these patients.”
Sanjay Kaul (Cedars Sinai) said that he is “not a big fan of stopping trials for efficacy unless there is a clear cut mortality benefit despite prespecified stopping rules.” However, he pointed out that it is “not unreasonable” to stop this trial early since “there is already large safety data for rivaroxaban.”
COMPASS is the second successful 27,000 patient cardiovascular study to be announced in less than a week. On February 2 Amgen reported that the FOURIER trial with the PCSK9 inhibitor evolocumab (Repatha) had successfully met its primary endpoint."
Recent JNJ News
- Apollo Eyes $5 Billion Investment in Intel; TSMC and Samsung Explore UAE Chip Projects, and More • IH Market News • 09/23/2024 10:32:25 AM
- Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt • Business Wire • 09/20/2024 10:53:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 08:19:26 PM
- Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims • Business Wire • 09/20/2024 07:43:00 PM
- RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer • PR Newswire (US) • 09/19/2024 10:54:00 PM
- Microsoft Boosts Share Buyback, Raises Dividends by 10%, Intel Secures Chip Deal with Amazon • IH Market News • 09/17/2024 10:40:35 AM
- Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer • PR Newswire (US) • 09/16/2024 06:50:00 AM
- New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer • PR Newswire (US) • 09/15/2024 06:30:00 AM
- RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer • PR Newswire (US) • 09/14/2024 01:45:00 PM
- RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer • PR Newswire (US) • 09/14/2024 07:10:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 08:44:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 08:43:45 PM
- TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease • PR Newswire (US) • 09/11/2024 10:22:00 PM
- Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw) • PR Newswire (US) • 09/10/2024 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 08:26:10 PM
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer • PR Newswire (US) • 09/08/2024 05:47:00 PM
- Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results • Business Wire • 09/05/2024 08:30:00 PM
- Qualcomm Develops Mixed Reality Glasses; Verizon to Boost Dividend, Eyes Acquisition; Samsonite Plans US Dual Listing • IH Market News • 09/05/2024 10:11:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:48:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/30/2024 07:51:09 PM
- Form N-PX - Annual Report of proxy voting record of management investment companies • Edgar (US Regulatory) • 08/29/2024 06:05:30 PM
- Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis • PR Newswire (US) • 08/29/2024 12:00:00 PM
- Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress • PR Newswire (US) • 08/27/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 08:26:20 PM
- IBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without Astronauts • IH Market News • 08/26/2024 12:58:21 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM